The Food and Drug Administration rejected Eagle Pharmaceuticals Inc.'s (Nasdaq: EGRX) heat stroke treatment Ryanodex. The stock price collapsed $16.67 to close at $53.37.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |